Filgrastim: The Importance of G-CSF in Treating Neutropenia and Other Blood Disorders

G-CSF (filgrastim)

Binds to a JAK/STAT receptor, stimulates proliferation and differentiation of progenitors already committed to the neutrophil lineage

G-CSF (granulocyte-colony stimulating factor) is a medication that stimulates the production of white blood cells (neutrophils) in the bone marrow. It is categorized as a hematopoietic (blood-forming) agent, and is used to treat conditions such as neutropenia (low neutrophil count), which is often seen in patients undergoing certain types of cancer treatment.

Filgrastim is a recombinant form of G-CSF, meaning that it is produced through genetic engineering techniques, and is used to stimulate the growth of white blood cells in patients experiencing neutropenia. It is typically administered via injection, either as a daily subcutaneous injection or a single-dose intravenous infusion.

In addition to treating neutropenia in cancer patients, filgrastim may also be used to mobilize stem cells for transplantation, treat certain types of leukemia and lymphoma, prevent infections in patients undergoing chemotherapy, and reduce the risk of infection in patients undergoing bone marrow transplant.

Like all medications, filgrastim can cause side effects. The most common side effects include injection site reactions, bone pain, headaches, and abdominal pain. More serious side effects, although rare, can include respiratory problems, allergic reactions, and ruptured spleen.

Overall, filgrastim is an important medication in the treatment of neutropenia and other conditions that affect white blood cell production, and can improve outcomes for patients undergoing cancer treatment or bone marrow transplant.

More Answers: